In the EU region available whole-virus vaccines are inactivated and adjuvanted. Vaccination of sows is common practice and reveals also a benefit to young pigs by prolonging the maternally level of antibodies. In vaccinated sows multiplication of viruses and virus shedding are significantly reduced. Recently, a live attenuated vaccine has gained market authorisation in USA.
IDT Biologika Animal Health produces a vaccine which protects against the three subtypes of swine influenza (H1N1, H1N2 and H3N2) which are the currently epidemiologically relevant subtypes. The vaccine significantly reduces the viral burden in the lungs and clinical signs. The vaccine is licensed for use from day 56 of age at a dose of 2 ml i.m., including in pregnant sows.
Its protective effect develops 7 days after the first vaccination.
In animals vaccinated between the age of 56 and 96 days, the vaccine confers 4 months immunity; for animals vaccinated after day 96, the duration of immunity is 6 months.
Maternally derived antibodies can be detected in suckling piglets until at least day 33 of age.
A vaccine against the pandemic influenza virus pdmH1N1(2009) completes the portfolio of IDT Biologika Animal Health influenza vaccines.
The vaccines reduces both viral lung load and viral excretion. The vaccine is licensed for the active immunization of pigs from the age of 8 weeks onwards at a dose of 1 ml i.m.
Its protective effect develops 7 days after the basic vaccination.
In animals vaccinated after 8 weeks onwards the vaccine confers 3 months immunity. Maternally derived antibodies in piglets can be detected for approximately 5 – 8 weeks after birth.
Figure 2: Vaccination schedule against pdmH1N1(2009).